Suppr超能文献

低蛋白血症与药代动力学:当对一个基本概念的误解导致数十年反复出现错误时。

Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades.

作者信息

Gandia Peggy, Decheiver Sarah, Picard Manon, Guilhaumou Romain, Baklouti Sarah, Concordet Didier

机构信息

Laboratoire de Pharmacocinétique et Toxicologie Clinique, Institut Fédératif de Biologie, CHU de Toulouse, 330 avenue de Grande-Bretagne, CEDEX 9, 31059 Toulouse, France.

INTHERES, Université de Toulouse, UMR 1436, INRAE, ENVT, 23 Chemin des Capelles, CEDEX 3, 31076 Toulouse, France.

出版信息

Antibiotics (Basel). 2023 Mar 4;12(3):515. doi: 10.3390/antibiotics12030515.

Abstract

Surprisingly, misinterpretation of the influence of hypoalbuminemia on pharmacokinetics and the clinical effects of drugs seems to be a current problem, even though hypoalbuminemia has no impact on the pharmacologically active exposure. Exceptions to this fact are highly protein-bound anaesthetics with high elimination capacity (i.e., <5 drugs on the market). To assess the frequency of misinterpretation of the influence of hypoalbuminemia on pharmacokinetics and the clinical effects of drugs between 1975 and 2021, a PubMed literature review was conducted. Each paragraph on albumin binding was classified as correct, ambiguous or incorrect, creating two acceptable categories: (1) content without any errors, and (2) content containing some incorrect and/or ambiguous statements. The analyses of these articles showed that fewer than 11% of articles contained no interpretation errors. In order to contain this misinterpretation, several measures are proposed: (1) Make the message accessible to a wide audience by offering a simplified and didactic video representation of the lack of impact of albumin binding to drugs. (2) Precise terminology (unbound/free form/concentration) should be used for highly bound drugs. (3) Unbound/free forms should be systematically quantified for highly plasma protein bound drugs for clinical trials as well as for therapeutic drug monitoring.

摘要

令人惊讶的是,尽管低白蛋白血症对药物的药理活性暴露没有影响,但对低白蛋白血症对药代动力学和药物临床效果的影响存在误解似乎是当前的一个问题。这一事实的例外情况是具有高消除能力的高蛋白结合麻醉剂(即市场上不到5种药物)。为了评估1975年至2021年间低白蛋白血症对药代动力学和药物临床效果影响的误解频率,进行了一项PubMed文献综述。关于白蛋白结合的每一段内容都被分类为正确、模糊或错误,形成两个可接受的类别:(1)无任何错误的内容,以及(2)包含一些不正确和/或模糊陈述的内容。对这些文章的分析表明,不到11%的文章没有解释错误。为了遏制这种误解,提出了几项措施:(1)通过提供关于白蛋白与药物结合缺乏影响的简化且有教育意义的视频呈现,让广大受众能够理解相关信息。(2)对于高度结合的药物,应使用精确的术语(未结合/游离形式/浓度)。(3)对于高度血浆蛋白结合的药物,在临床试验以及治疗药物监测中,应系统地对未结合/游离形式进行定量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cc0/10044130/2c167fac141a/antibiotics-12-00515-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验